Dry Eye Renaissance: Escalating Cases Meet With Innovation

Two decades ago, managing dry eye disease was straightforward. Practitioners were able to offer a few options: artificial tears, prescription cyclosporine ophthalmic emulsion (Restasis; Allergan), and punctal occlusion.

Since then, our options have multiplied. With novel treatments and diagnostics approved by the FDA and additional strategies in the pipeline, we’ve entered an era of innovative management for this common condition—a kind of dry eye renaissance.

See More

Our In Focus newsletter is published once a month and has thousands of subscribers. To help you keep in touch, you can subscribe here.